^
    1d
    CurbMF: A Study of VG712 in Patients With Mycosis Fungoides (clinicaltrials.gov)
    P2, N=386, Not yet recruiting, Virogen Biotechnology Inc.
    New P2 trial
    |
    Poteligeo (mogamulizumab-kpkc) • Resimmune (VG712)
    1d
    CELESTIAL-301: SynKIR-310 for Relapsed/Refractory B-NHL (clinicaltrials.gov)
    P1, N=36, Recruiting, Verismo Therapeutics | N=18 --> 36
    Enrollment change • First-in-human
    |
    BCL2 (B-cell CLL/lymphoma 2)
    1d
    IPH6501-101: Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=23, Terminated, Innate Pharma | N=184 --> 23 | Trial completion date: Dec 2028 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2028 --> Feb 2026; Following Completion of dose escalation, the study has been discontinued as part of the Company's strategic priorization of its pipeline.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    IPH6501
    1d
    REBEL: External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Utah
    New P1 trial
    |
    Epkinly (epcoritamab-bysp) • Columvi (glofitamab-gxbm)
    1d
    Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=43, Recruiting, Beijing Tongren Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • Xpovio (selinexor) • pomalidomide
    1d
    STOP-CLL-DCT: Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial
    1d
    Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL (clinicaltrials.gov)
    P2, N=40, Recruiting, Massachusetts General Hospital | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    2d
    KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, TCRx Therapeutics Co.Ltd | N=30 --> 18 | Initiation date: May 2025 --> Sep 2025 | Trial primary completion date: Jun 2028 --> Dec 2028
    Enrollment change • Trial initiation date • Trial primary completion date
    |
    CD19 positive
    2d
    A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Ou Bai, MD/PHD
    New trial • Real-world evidence
    |
    Jaypirca (pirtobrutinib)
    2d
    The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    2d
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=408, Recruiting, AstraZeneca | N=276 --> 408 | Trial completion date: Feb 2028 --> Jun 2029
    Enrollment change • Trial completion date
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    2d
    Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=76, Recruiting, N.N. Alexandrov National Cancer Centre
    New trial • Real-world evidence
    |
    CD19 (CD19 Molecule)